Please assess the completion status of the following clinical trial:

Trial Title: Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 85 years old~* Able to provide informed consent~* AICD implanted for primary prophylaxis against sudden cardiac death~* AICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes~* CAD with prior myocardial infarction (\>60 days prior to enrollment)~* AICD or ECG documentation of ventricular arrhythmia responsible for appropriate AICD therapy (\> 3 ATP or ≥ 1 appropriate Shock)~Exclusion Criteria:~* Contraindication or allergy to contrast media, routine procedural medications or catheter materials~* Contraindication to an interventional procedure~* Current or previous (within 3 months) antiarrhythmic therapy~* Absolute contraindication to amiodarone or other AAD~* New York Heart Association (NYHA) functional class IV~* Stroke within the past 90 days~* Unstable angina~* Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome~* Subjects with active ischemia that are eligible for revascularization~* Life expectancy less than 6 months~* Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation~* Untreated hypothyroidism or hyperthyroidism. Subjects who are euthyroid on thyroid hormone replacement therapy are acceptable.~* Current enrollment in another investigational drug or device study.~* Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the Subject for the entire study period.~* Absolute contra-indication to the use of heparin and or warfarin.~* Documented intra-atrial thrombus, ventricular thrombus (\< 6 months after detection of thrombus), tumor, or another abnormality, which precludes catheter introduction.~* Previous VT ablation~* Are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Anti-arrhythmic drug therapy (Type: ACTIVE_COMPARATOR): Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
- Catheter ablation (Type: ACTIVE_COMPARATOR): Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).